Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVEC
- PMID: 16442496
- DOI: 10.1016/j.bbrc.2006.01.052
Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVEC
Abstract
Fenofibrate improves endothelial function by lipid-lowering and anti-inflammatory effects. Additionally, fenofibrate has been demonstrated to upregulate endothelial nitric oxide synthase (eNOS). AMP-activated protein kinase (AMPK) has been reported to phosphorylate eNOS at Ser-1177 and stimulate vascular endothelium-derived nitric oxide (NO) production. We report here that fenofibrate activates AMPK and increases eNOS phosphorylation and NO production in human umbilical vein endothelial cells (HUVEC). Incubation of HUVEC with fenofibrate increased the phosphorylation of AMPK and acetyl-CoA carboxylase. Fenofibrate simultaneously increased eNOS phosphorylation and NO production. Inhibitors of protein kinase A and phosphatidylinositol 3-kinase failed to suppress the fenofibrate-induced eNOS phosphorylation. Neither bezafibrate nor WY-14643 activated AMPK in HUVEC. Furthermore, fenofibrate activated AMPK without requiring any transcriptional activities. These results indicate that fenofibrate stimulates eNOS phosphorylation and NO production through AMPK activation, which is suggested to be a novel characteristic of this agonist and unrelated to its effects on peroxisome proliferator-activated receptor alpha.
Similar articles
-
PPARalpha activators upregulate eNOS activity and inhibit cytokine-induced NF-kappaB activation through AMP-activated protein kinase activation.Life Sci. 2008 Apr 9;82(15-16):884-91. doi: 10.1016/j.lfs.2008.02.002. Epub 2008 Feb 16. Life Sci. 2008. PMID: 18346759
-
Statins activate AMP-activated protein kinase in vitro and in vivo.Circulation. 2006 Dec 12;114(24):2655-62. doi: 10.1161/CIRCULATIONAHA.106.630194. Epub 2006 Nov 20. Circulation. 2006. PMID: 17116771
-
Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells.Arterioscler Thromb Vasc Biol. 2004 Apr;24(4):658-63. doi: 10.1161/01.ATV.0000118682.58708.78. Epub 2004 Jan 29. Arterioscler Thromb Vasc Biol. 2004. PMID: 14751809
-
Phosphorylation of PPARs: from molecular characterization to physiological relevance.Biochimie. 2005 Jan;87(1):33-8. doi: 10.1016/j.biochi.2004.11.010. Biochimie. 2005. PMID: 15733734 Review.
-
[Role of AMP-activated protein kinase in the cardiovascular system].Nihon Rinsho. 2006 Jul;64 Suppl 5:143-50. Nihon Rinsho. 2006. PMID: 16897858 Review. Japanese. No abstract available.
Cited by
-
Fenofibrate Inhibits Cytochrome P450 Epoxygenase 2C Activity to Suppress Pathological Ocular Angiogenesis.EBioMedicine. 2016 Nov;13:201-211. doi: 10.1016/j.ebiom.2016.09.025. Epub 2016 Sep 30. EBioMedicine. 2016. PMID: 27720395 Free PMC article.
-
The physiology of bilirubin: health and disease equilibrium.Trends Mol Med. 2023 Apr;29(4):315-328. doi: 10.1016/j.molmed.2023.01.007. Epub 2023 Feb 22. Trends Mol Med. 2023. PMID: 36828710 Free PMC article. Review.
-
Enhancing the metabolic substrate: PPAR-alpha agonists in heart failure.Heart Fail Rev. 2012 Jan;17(1):35-43. doi: 10.1007/s10741-010-9208-0. Heart Fail Rev. 2012. PMID: 21104312 Review.
-
CEPT1-Mediated Phospholipogenesis Regulates Endothelial Cell Function and Ischemia-Induced Angiogenesis Through PPARα.Diabetes. 2021 Feb;70(2):549-561. doi: 10.2337/db20-0635. Epub 2020 Nov 19. Diabetes. 2021. PMID: 33214136 Free PMC article.
-
Effects of WY-14,643 on the phosphorylation and activation of AMP-dependent protein kinase.Arch Biochem Biophys. 2009 May 1;485(1):10-5. doi: 10.1016/j.abb.2009.02.006. Epub 2009 Feb 21. Arch Biochem Biophys. 2009. PMID: 19236843 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources